Terms: = Gastric cancer AND MYH9, P35579, 4627, ENSG00000100345, DFNA17 AND Prognosis
4 results:
1. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to myh9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
2. Nuclear myh9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis.
Ye G; Yang Q; Lei X; Zhu X; Li F; He J; Chen H; Ling R; Zhang H; Lin T; Liang Z; Liang Y; Huang H; Guo W; Deng H; Liu H; Hu Y; Yu J; Li G
Theranostics; 2020; 10(17):7545-7560. PubMed ID: 32685004
[No Abstract] [Full Text] [Related]
3. Mucin 17 inhibits the progression of human gastric cancer by limiting inflammatory responses through a myh9-p53-RhoA regulatory feedback loop.
Yang B; Wu A; Hu Y; Tao C; Wang JM; Lu Y; Xing R
J Exp Clin Cancer Res; 2019 Jul; 38(1):283. PubMed ID: 31262330
[TBL] [Abstract] [Full Text] [Related]
4. cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on cancer/International Union Against cancer cancer Staging Manuals.
Rice TW; Rusch VW; Ishwaran H; Blackstone EH;
Cancer; 2010 Aug; 116(16):3763-73. PubMed ID: 20564099
[TBL] [Abstract] [Full Text] [Related]
